New exclusivity up to 11 years for medicines in the EU: implications from a patent perspective
Last December, the Council and the European Parliament reached an agreement on the “Pharma package”, which is an updated set of rules that aims to safely, justly, efficiently, affordably and fairly improve patient access to drugs, reduce regulatory burden and, lastly, strengthen competitiveness in the European pharmaceutical industry in relation to other regions outside the … Read more